MicroRNA-protein complexes (microRNPs) can activate translation of target reporters and specific mRNAs in quiescent (i.e., G0) mammalian cell lines. Induced quiescent cells, like folliculated immature oocytes, have high levels of cAMP that activate protein kinase AII (PKAII) to maintain G0 and immature states. We report microRNAmediated up-regulated expression of reporters in immature Xenopus laevis oocytes, dependent on Xenopus AGO or human AGO2 and on FXR1, as in mammalian cells. Importantly, we find that maintenance of cAMP levels and downstream PKAII signaling are required for microRNA-mediated up-regulated expression in oocytes. We identify an important, endogenous cell state regulator, Myt1 kinase, as a natural target of microRNA-mediated upregulation in response to xlmiR16, ensuring maintenance of oocyte immaturity. Our data reveal the physiological relevance of cAMP/PKAII-controlled posttranscriptional gene expression activation by microRNAs in maintenance of the immature oocyte state.
MicroRNA-protein complexes (microRNPs) can activate translation of target reporters and specific mRNAs in quiescent (i.e., G0) mammalian cell lines. Induced quiescent cells, like folliculated immature oocytes, have high levels of cAMP that activate protein kinase AII (PKAII) to maintain G0 and immature states. We report microRNAmediated up-regulated expression of reporters in immature Xenopus laevis oocytes, dependent on Xenopus AGO or human AGO2 and on FXR1, as in mammalian cells. Importantly, we find that maintenance of cAMP levels and downstream PKAII signaling are required for microRNA-mediated up-regulated expression in oocytes. We identify an important, endogenous cell state regulator, Myt1 kinase, as a natural target of microRNA-mediated upregulation in response to xlmiR16, ensuring maintenance of oocyte immaturity. Our data reveal the physiological relevance of cAMP/PKAII-controlled posttranscriptional gene expression activation by microRNAs in maintenance of the immature oocyte state.
M icroRNAs are 19-to 23-nt RNAs that serve as posttranscriptional regulators of gene expression when recruited into effector complexes with a core Argonaute protein, AGO2 (eIF2C2) in mammals. These microRNA-protein complexes (microRNPs) bind the target mRNA, normally within its 3′-UTR, and regulate translation and decay of mRNAs (1) .
We previously demonstrated that microRNPs can effect translation activation of minimal target reporters and specific mRNAs in quiescent mammalian cells (2) . Quiescence refers to nondividing G0 and G0-like states with specific gene expression programs that dividing cells can enter for extended periods of time in a reversible manner. The G0 state can be naturally programmed during differentiation or development or induced in cultured cells. DNA replication ceases and gene expression skews toward maintaining the G0 state and preventing promiscuous entry into other states (3) .
Like G0 cells, the Xenopus laevis prophase I-arrested immature oocyte does not proliferate or replicate DNA (4) . The immature oocyte is surrounded by follicle cells that maintain high cAMP levels and downstream protein kinase A (PKA) signaling, thereby inhibiting maturation (5) . Defolliculation and progesterone treatment cause a loss of signaling through G protein-coupled receptors, leading to altered PKA signaling, loss of the nuclear membrane [called germinal vesicle (GV) breakdown], and maturation (5) . The cAMP-inducible PKA holoenzyme acts as PKAI or PKAII as a result of modulation of the catalytic subunit by alternative cofactors, repressor I (RI) or II (RII) subunits (6) ; both RI and RII respond to cAMP levels, with RII requiring higher levels of cAMP. PKAI is present in proliferating cells and various tumors in which RI is overexpressed; PKAII is observed in arrested and nonproliferating cells in which RII predominates (6) . Like immature oocytes, the G0 state in some mammalian cells can be elicited by increasing cAMP levels to induce PKAII (6, 7) .
The oocyte up-regulates the expression of genes essential for maintaining the immature state (8) . Among these is the cell state regulator, Myt1 kinase, which is up-regulated at the translational level as the immature oocyte advances from stages I-III to stages IV-VI (8) . Myt1 is required for CDC2 phosphorylation and consequent inactivation of prematuration promoting factor (pre-MPF, comprised of cyclin B2 and CDC2) (8, 9) , preventing maturation.
Here, we investigated whether microRNA-mediated activation occurs in naturally quiescent-like X. laevis immature oocytes. We find that activation is regulated by the G0-controlling cAMP/ PKAII pathway and identify an endogenous microRNA in the immature oocyte required to increase expression of the cell state regulator Myt1. Thus, microRNA-mediated posttranscriptional upregulation is relevant for maintenance of the immature oocyte state.
Results
Exogenous MicroRNAs Activate Expression of Target mRNA Reporters in the Immature Oocyte. We tested microRNA-mediated expression in the G0-like immature X. laevis oocyte with luciferase reporters used in mammalian cells (2) . We injected DNA constructs with a CMV promoter and bovine growth hormone polyadenylation sequence or in vitro-transcribed capped, unadenylated RNAs into the nucleus of folliculated stage IV-VI oocytes. We routinely included: (i) coinjection of a Renilla luciferase reporter (REN) bearing a nonspecific polylinker sequence in its 3′-UTR to normalize for injection and overall translation status; (ii) a Firefly luciferase reporter with either a mutated 3′-UTR or a polylinker sequence (control; CTRL) of the same size as the 3′-UTR of the test reporter; and (iii) assessment of RNA levels.
When a Firefly luciferase plasmid bearing TNF-α AU-rich elements (AREs) in its 3′-UTR was coinjected with the corresponding microRNA, miR369-3p (2), a five-to sixfold increase in expression was observed relative to the control microRNA, let-7a, or the CTRL reporter (Fig. 1A ). An increase in expression can arise from relief of repression, whereby the increased expression is equal to and not greater than the control (i.e., restoration of general translation), or activation, in which the increased expression is greater than the control (i.e., stimulation over general translation); the control is either a no-microRNA target reporter (i.e., CTRL) or a mismatched control microRNA added with the test reporter (2, 10) . Expression of the ARE reporter with miR369-3p was higher than the reference controls, CTRL and the ARE reporter with a nonmatching microRNA, suggesting stimulation.
We then injected the CX reporter plasmid, which harbors four copies of a target site for a synthetic microRNA, miRcxcr4, which had previously exhibited translation activation in G0 mammalian cells and translation repression in cycling cells (2, 11) . A time course of luciferase activity revealed increased expression in the presence of miRcxcr4 compared with the control let-7a microRNA; a fourfold enhancement at 3 h after injection increased to sixfold at 5 h (Fig. 1B) . Cytoplasmic levels of the mRNA did not exceed that of the microRNA until 6 h, when the exogenous microRNA levels with a half-life of approximately 30 min decreased ( Fig. S1 A and C and SI Methods). Values increased only for the microRNA target, CX, and not for the control REN (Fig. S1D) , suggesting specific activation of the microRNA target. The 4-h time point was chosen for comparison in subsequent experiments. Luciferase protein half-lives (Fig. S1B ), CX total (Fig. 1C) , and cytoplasmic mRNA ( Fig. 1D and Fig. S1C ) levels were comparable in the presence or absence of miRcxcr4. Comparable results were obtained by injecting the corresponding capped reporter mRNAs and microRNAs into the GV of folliculated oocytes (Fig. 1E) . These results suggest that microRNAmediated up-regulated expression at the translational level can be achieved in the natural, G0-like immature oocyte.
Up-Regulated Expression by MicroRNAs Occurs Only in Folliculated
Immature Oocytes. Up-regulated translation of the CX reporter by miRcxcr4 was observed in folliculated but not in defolliculated immature oocytes (Fig. 1E) . Likewise, when oocytes were matured with progesterone, the sixfold stimulation of expression of the CX reporter was converted to a fourfold repressive effect (Fig. 1F) . Thus, maturation, like defolliculation, correlates with a loss of up-regulated translation by microRNAs. (B) Expression of PKA repressor I (RI) abrogates, whereas repressor II (RII) activates, translation of the CX reporter in the presence of miRcxcr4 and of the AGO2-tethered reporter in oocytes. (C) Blocking the PKA pathway (dominant negative PKA, dnPKA) or the downstream PAK pathway (using a dominant negative inhibitor, AID) causes loss of up-regulation of CX by miRcxcr4 in folliculated immature oocytes compared with a mutant form of the inhibitor, mtAID, or a GFP control. Expression of a constitutively active PAK, L107F, enables upregulated expression of CX by miRcxcr4 in defolliculated oocytes whereas a kinase inactive form, K299R, does not. Expression of a constitutively active RAFv600E or a constitutively active MEK, MEKDD (both are turned off by PAK), blocks up-regulated expression of CX by miRcxcr4 compared with the GFP control in folliculated immature oocytes. L107F and K299R samples used defolliculated oocytes, whereas all other samples were folliculated oocytes. All reporters were in vitro-transcribed, capped luciferase RNAs; the signaling proteins were expressed from plasmids. Firefly luciferase values were normalized against REN.
cAMP/PKA Pathway Is Required for Up-Regulated Translation in Xenopus Oocytes. cAMP levels increase in some G0 mammalian cells (6, 7) and in immature folliculated oocytes ( Fig. S2A ) (5) . Maturation can be prevented by adding inhibitors of phosphodiesterases and nondegradable cAMP analogues (5). Accordingly, the loss of translation activation of the CX reporter by miRcxcr4 upon defolliculation of immature oocytes can be reversed by addition of the phosphodiesterase inhibitor papaverine ( Fig. 2A) . Dibutyryl cAMP, an analogue that increases PKA activity (12) , elicits increased translation of the CX reporter in the presence of miRcxcr4 or of an AGO2-tethered reporter (2) in defolliculated oocytes (Fig. S2B ). In accord with observations of PKAII activity in arrested mammalian cells (6, 7) , injection of RII (PKAII activation) or the catalytic subunit (C) plasmids into oocytes activated translation with miRcxcr4 and not with the control microRNA, let-7a, whereas RI (PKAI activation), associated with proliferation, did not ( Fig. 2B and Fig. S2C ). Overexpression of dominant negative PKA inhibited up-regulation in oocytes, confirming that PKA is required for translation activation (dnPKA; Fig. 2C ) in immature Xenopus oocytes. The PKA/cAMP pathway signals to the p21-activated kinase (PAK) to turn off the growth factor-stimulated MAPK proliferative pathway in mammalian cells; in oocytes, cAMP and PKA function with PAK to promote maintenance of the immature state (13) . Injecting a dominant-negative inhibitor of PAK (AID) into immature folliculated oocytes prevents translation activation, whereas a mutant form of the inhibitor that cannot bind and block the active site of PAK (mtAID) does not ( Fig. 2C ; compare AID vs. mtAID). In defolliculated oocytes, a constitutively active form of PAK (L107F) promotes activation whereas a catalytically inactive form (K299R) does not ( Fig. 2C ; compare L107F vs. K299R samples, which are defolliculated oocytes), suggesting that the PAK pathway is required for microRNA-mediated up-regulation in oocytes. A constitutively active form of RAF, which activates MAPK, or a constitutively active MAPK prevents activation ( Fig.  2C ; RAFv600E and MEKDD), arguing that cAMP-mediated activation by microRNAs involves turning off downstream MAPK and involves PAK; additional pathways may also affect activation.
Up-Regulated Expression by MicroRNAs in Immature Oocytes Requires
Human AGO2 or Xenopus AGO and FXR1. We asked whether AGO and FXR1, factors essential for translation activation in G0 mammalian cells (2) , are also involved in the oocyte. Western blotting with an anti-AGO2 antibody as well as an AGO antibody that recognizes AGOs 1 to 4 ( Fig. 3A and Fig. S3 A and C) revealed a band in immature oocyte extracts. cDNA sequencing identified an allele, which matched one of two database entries for Xenopus eIF2C2 (NM_001093519) and is similar to a second Xenopus eIF2C2 sequence (EU338243). As the cDNA has not been characterized with known human AGO2 functions such as slicer activity (1), we refer to it as xlAGO based on its sequence identity to the Argonaute family.
When oocytes depleted of FXR1 or AGO by antisense for 12 to 16 h (Fig. 3A, Fig. S3D , and SI Methods) are injected with the CX reporter and the corresponding miRcxcr4, no translation activation is observed (Fig. 3B ) compared with a four-to fivefold translation up-regulation in mock-treated oocytes. In vitrotranscribed mRNAs of resistant forms of Xenopus FXR1 and AGO (λNXlFXR1 and λNXlAGO; Fig. 3 A and B) or of human FXR1 and AGO2 (Fig. S3B) rescue translation, suggesting a conserved function between humans and Xenopus; human AGO1, AGO3, and AGO4 have less significant effects on activation (Fig. S3B) . When λN-tagged human or Xenopus AGO and FXR1 are individually expressed along with the 5B Box Firefly luciferase tethering reporter, either protein causes translation activation, whereas control mutant proteins and vectors do not ( Fig. 3 C and D) . Finally, to test whether association with the mRNA in Xenopus oocytes is microRNA-dependent, we analyzed AGO immunoprecipitates for the Firefly luciferase mRNA by RT-PCR. Fig. 3E shows that Xenopus AGO associates significantly with the CX reporter (but not CTRL mRNA) in the presence but not absence of miRcxcr4. These data argue that Xenopus AGO and FXR1 have retained at least the translation activation function of their mammalian counterparts.
Endogenous microRNA with a Heterogeneous 5′ End, xlmiR16, UpRegulates Expression of Myt1 mRNA in the Oocyte. We searched for potential targets reported to be regulated at the translation level during oocyte stages III-VI (8) . Myt1 protein levels rise across the immature stages without a concomitant increase in mRNA levels and are required for CDC2 phosphorylation and inactivation of pre-MPF (8, 9) . Myt1 mRNA harbors a 1758-nt 3′-UTR that contains seven potential xlmiR16 target sites ( Fig. 4A ) that might engage in noncanonical base pairing. An siRNA antisense to the loop region of precursor (pre-) xlmiR16 reduced mature xlmiR16 levels in oocytes (SI Methods and Fig. S4A ). The endogenous xlmiR16 (14) appears more stable (Fig. S4B ) than exogenous microRNAs (Figs. S1A, i, and S4C), requiring more than 6 h for siRNA-mediated antisense depletion, likely because of interference with processing or stability instead of cleavage. Reporters carrying the entire Myt1 3′-UTR or a 528-nt segment bearing the seven putative sites exhibit up-regulated expression in the presence of xlmiR16 (Fig. 4A ) independent of RNA levels (Fig. 4B) . We found that one site (1,284 nt from the stop codon) is necessary for up-regulation, as mutating this site (mt3Myt1; SI Methods) causes a loss of activation that is not further decreased by the loss of xlmiR16 (Fig. 4A ). To determine whether the effect of xlmiR16 is direct, we made a correspondingly mutated xlmiR16, xlmt3miR16 (SI Methods), which should restore base pairing; we find that the compensatory microRNA restores translation activation (Fig. 4A ) without altering mRNA levels (Fig. 4B) . The xlmiR16 target sequence in the Myt1 3′-UTR defined earlier is complementary to nucleotides 4 to 10 (or 4-12) of the microRNA rather than to nucleotides 2 to 7/8, as expected from the seed rules (15) . Therefore, either the Myt1 target site uses noncanonical base pairing (16, 17) or the endogenous microRNA has an altered 5′ end that enables functional interactions (Fig. 4C , potential base pairing with Myt1 shown). We determined the 5′ end of the microRNA by splint ligation by using oligonucleotides designed to capture stepwise shortened versions of the 5′ end of xlmiR16: B1 is the full 5′ end, and B2, B3, and B4 are successively 1, 2, and 3 nt shorter. The B3 version (truncated by 2 nt at the 5′ end of xlmiR16) is abundant in both total oocyte RNA and in AGO immunoprecipitates (Fig. 4C) , suggesting that B3/ xlmiR16 is the predominant functional form of the microRNA, whereas the nontruncated version of xlmiR16 (B1/xlmiR16) is only faintly detectable. To prove that B3/xlmiR16 can up-regulate translation by acting on the full-length Myt1 3′-UTR (potential base pairing with Myt1 shown in Fig. 4C ), luciferase assays were repeated after depleting endogenous xlmiR16 and adding back various 5′-truncated forms. Addition of B3/xlmiR16 restores translation activation (Fig. 4D) containing the labeled 14-nt acceptor oligo and RNAs isolated from anti-AGO2 or -FLAG (control) immunoprecipitates (Ip). XlmiR16 variants that are successively truncated by one nucleotide at the 5′ end (B1/xlmiR16-B4/xlmiR16) were detected using DNA bridge oligos B1-B4, complementary to the first 16 nt of the predicted microRNAs. The predicted full-length form, B1/xlmiR16, is only faintly visible in the sample immunoprecipitated with anti-AGO2, suggesting that it is less abundant than B3/xlmiR16, which is revealed by the B3 bridge oligo to be an abundant microRNA in anti-AGO2 immunoprecipitates. Lanes marked B1/xlmiR16 and B3/xlmiR16 show synthetic miR16 RNAs as size controls. Underlined nucleotides are required for interaction with the Myt1 3′-UTR. Base pairing between Myt1 target site and B1/xlmiR16 or B3/xlmiR16 are shown. (D) Oocytes treated with mock (let-7a) or si-pre-miR16 were coinjected with synthetic xlmiR16 forms to assess rescue of full-length Myt1 3′-UTR reporter translation. Firefly luciferase values were normalized to REN. B1/xlmiR16 undergoes trimming to the B3/xlmiR16 form and rescues translation to a lesser extent than B3/xlmiR16.
To confirm that the site at 1284 in Myt1 3′-UTR is critical for translation up-regulation, we designed an LNA oligonucleotide antisense to this site and its adjacent sequences, similar to the protectors developed earlier (18) . When LNAmyt is injected into oocytes (Fig. 5A ), translation activation of luciferase reporters bearing the 528-nt Myt1 3′-UTR (or full length) is abrogated. Loss of translation activation is also observed when endogenous xlmiR16 levels are depleted by si-pre-miR16 (Fig. 5A) ; activation is rescued by add-back of synthetic xlmiR16 (B3/xlmiR16). Conversely, the loss of translation up-regulation observed with the mtMyt1 reporter is rescued by addition of a B3/xlmiR16 form, xlmtmiR16, harboring compensatory mutations that restore base pairing with the mutant mtMyt1 3′-UTR (Fig. 5A ).
MicroRNA-Activated Expression Is Required to Maintain the Oocyte
Immature State. Ablation of Myt1 kinase in the oocyte leads to CDC2 dephosphorylation and loss of the immature state (8, 9) . We asked whether translation activation via xlmiR16 is essential for maintenance of the immature state. First, we treated oocytes with the LNA protector, LNAmyt, to block translation activation of the endogenous Myt1 mRNA. As shown in Fig. 5B , increasing levels of LNAmyt reduce endogenous Myt1 protein. Injection of a Myt1 gene construct with a polylinker as its 3′-UTR (Mytctrlutr), which should not bind LNAmyt, partially restores Myt1 levels ( Fig. 5B) , demonstrating that the loss of translation activation by LNAmyt is through the Myt1 3′-UTR. Second, we depleted endogenous xlmiR16 levels by using si-pre-miR16 ( Fig.  5C ) and observed a corresponding loss of Myt1 protein levels (Fig. 5D ). We then asked whether xlmiR16-mediated translation activation of Myt1 is physiologically essential by examining the marker of immaturity, phosphorylated CDC2. Phosphorylated CDC2 levels dramatically decrease ( 
Discussion
MicroRNPs exhibit versatility in their control of gene expression, dependent on the specific mRNA 3′-UTR (10, 19) . Translational activation in alternative cell states, such as the immature oocyte, provides a means of gene expression to maintain the state. We previously demonstrated that microRNPs can activate translation of minimal target reporters in G0 mammalian cells (2). Here we have documented microRNA-mediated translation activation in the naturally G0-like X. laevis immature oocyte. xlAGO and FXR1 proteins are required, as in mammalian G0-induced activation. We further demonstrate that microRNAdependent activation is dependent on cAMP/PKA signaling in X. laevis oocytes. Our data argue that xlmiR16 is required in part for oocyte immaturity and that microRNA-mediated activated expression of endogenous mRNAs in the X. laevis oocyte is physiologically relevant for maintenance of the immature state.
A common feature of the immature Xenopus oocyte and mammalian G0 state is that cAMP signaling is required to sustain immaturity (5, 20) and G0 in some mammalian cells (7) . Loss of the oocyte immature state leads to loss of microRNA-mediated activation ( Fig. 1 E and F) , as does loss of the mammalian G0 state (2) . cAMP binds the R subunit and activates PKA dependent on the predominance of RI, associated with proliferation or RII, associated with arrested cells (6) . Overexpression of RII/PKAII (but not RI) in oocytes leads to activated expression in the presence of microRNAs (Fig. 2B ). PKAII signaling is induced by a relative increase in cAMP levels (21) observed in immature oocytes and G0, rather than the total levels of cAMP; therefore, there is a loss of activation controlled by PKAII upon defolliculation ( Fig. 1E ) and loss of adenyl cyclase stimulation. However, the effect is more pronounced in mature oocytes (5) in which GV breakdown increases phosphodiesterase activity and loss of adenyl cyclase activity and MPF activation perpetuates the decreased cAMP response via a feedback loop (5) . Stabilized persistence of the low cAMP state upon oocyte maturation (5) and in proliferating cells is sufficient for RI/PKA I activity (12, 21) , which correlates with translation repression (Fig. 2B) after maturation (Fig. 1F) . A second common feature of oocytes and G0 cells is that the repressive microRNP cofactor GW182 (22) appears compromised: GW182 interaction with AGO is not detected in immature or mature oocytes and in mouse oocytes, which fail to show significant repression (23) , and is reduced in G0 mammalian cells (24) , in which activation is observed (2) . AGO that cannot interact with GW182 can fail to repress translation (23, 25) , cause activation of unadenylated target reporters, or repress via the cap (26) , likely decided by additional determinants. Specific mRNAs may adapt to the absence of the repressive AGO-GW182 interaction in oocytes and G0 (2, 23, 24) and instead recruit a translation activating AGO-FXR1 complex (which relocalizes to polysomes in G0) (2) . Regulation by cAMP may give AGO-FXR1 an advantage in oocytes and G0, in which AGO-GW182 interaction is reduced (2, 23, 24) , consistent with a recent report that FXR1 function in zebrafish requires PAK (27) , a kinase downstream of cAMP required for microRNA-mediated activation in oocytes (Fig. 2C) .
The potential mechanisms of enhanced expression, including mRNA stability and translation up-regulation, remain to be explored. Although the total and cytoplasmic levels of the mRNAs ( Fig. 1 C and D and Fig. S1C ) do not change with the presence of interacting microRNA, effects of the cap and the poly(A) tail remain to be defined. The experiments were carried out with nonadenylated mRNAs, as enhanced expression compared with the increased levels observed with polyadenylated reporters could not be discerned. The need to inject into the nucleus for activation and the absence of activation in mature oocytes, which lack intact nuclei (Fig. 1F) , may result from the fact that mRNA translation effects are often decided by nuclear events (28) and that microRNP functions can involve a nuclear phase for AGO (29) .
MicroRNAs are less abundant relative to other small RNAs in Xenopus oocytes (14, 30) . The range of targets regulated may be expanded by trimming microRNAs in a flexible manner. A 5′-truncated version of B3/xlmiR16 (20 nt) in AGO complexes (Fig.  4C ) triggered more robust translation activation of Myt1 mRNA than the untruncated B1/xlmiR16 (Fig. 4D) .
Xenopus oocyte immaturity is maintained by critical phosphorylations that render pre-MPF inactive until maturation is induced (20) . Our results demonstrate that PKA-regulated microRNAmediated activation is essential for Myt1 expression (Figs. 4 and 5); Myt1 enables phosphorylation of CDC2, contributing to maintenance of the immature state (8, 9) ; loss of Myt1 translation leads to maturation (Figs. 5 C-E and Fig. S5 A and B) (9) . Oocyte immaturity can be rescued in part by restoring xlmiR16 (Figs. 5 C-E and Fig. S5A, lane 7) or by reexpressing Myt1 (Fig. S5 A,  lanes 4 and 8, and B) , suggesting that xlmiR16 is necessary for immaturity in part because it maintains the expression of the essential regulator, Myt1 (Figs. 4 and 5 and Fig. S5 ). Other targets and (undiscovered) microRNA functions likely also contribute to oocyte immaturity. The role of microRNAs in mediating up-regulated expression in the oocyte has implications for related physiological functions in G0 mammalian cells.
Methods
Oocytes. Human chorionic gonadotropin (hCG)-stimulated oocytes were manipulated as described in SI Methods. A total of 5 nL containing 0.0625 to 0.125 ng DNA plasmid, 0.01-0.1 fmol in vitro-transcribed luciferase reporter mRNAs, 375 fmol siRNA or microRNA, 37.5 ng of antisense or 10 ng of mRNAs were injected per oocyte with blue dextran dye to visualize delivery into the GV. Translation was assayed with a time course ranging from 1 to 6 h and compared at 4 h in hCG-treated oocytes. All experiments were conducted with folliculated immature stage IV-VI oocytes unless specified otherwise.
Plasmids and Reporters. All plasmids and reporters are described in SI Methods.
Luciferase Assay and Protein and RNA Analyses. Luciferase assays were performed as described (Promega). Oocytes were manually crushed in passive lysis buffer (Promega), and clarified by centrifugation at 2,000 × g for 5 m. Total oocyte extracts, immunoprecipitations, and RNA analyses are described in SI Methods. The average ratios of luciferase values were calculated with SDs. RNA levels were assessed in each experiment separately (not used to normalize the values graphed) and performed at least three times completely.
Supporting Information
Mortensen et al. 10 .1073/pnas.1105401108 SI Methods Oocyte Injections. Oocytes were harvested from hCG-treated frogs (1) . Injections were performed using Drummond Nanoject II system with volumes of 5 nL for reporters and plasmids (into the nucleus only) and 50 nL for RNAs expressing proteins (cytoplasm) or antisense oligonucleotides and siRNAs (animal pole side) as described later. Injections of 18 nL for reporters and plasmids into the nucleus gave similar results. It is essential that all reporters (DNA plasmids and RNA reporters) and microRNAs are injected into the GV, as cytoplasmic injections do not yield activation. Oocyte samples marked defolliculated were given an overnight rest after defolliculation before harvest/further analyses. Apart from this, all of the extracts (for RNA and protein analyses) were prepared only after collagenase treatment followed by manual defolliculation and examination to ensure complete defolliculation (1) .
GVs of folliculated oocytes at stages IV/V rather than VI can be more easily injected. The tip of the needle should be long (but not too flexible) and broken off to have a slanted edge. We injected small quantities (0.01 fmol; 0.1 fmol of the reporters) to avoid escape into the cytoplasm that would produce erroneous background readings. Expressing DNA constructs by GV injection was most reliable.
DNA Plasmids and Antisense. Plasmids at 0.0625 ng (for reporters) and 0.0625 to 0.125 ng (for protein expression) per oocyte were injected. mRNAs for protein expression were injected at 50 nL into the cytoplasm with 10 ng mRNA per oocyte. Antisense DNA oligonucleotides or siRNAs were injected into the animal pole side at 37.5 ng per oocyte. When Argonautes, FXR1, PAKs, or other signaling regulators were expressed, these transcribed mRNAs (Argonautes, FXR1) or plasmids (signaling regulators) were injected 4 h before injection of the reporter mRNAs and micro-RNA or of the antisense. In the case of AGO, FXR1 antisense and its rescue by human and Xenopus Argonaute and FXR1 clones, or in the case of other antisense and rescue, the transcribed Argonaute, FXR1, or GFP control mRNAs were first injected into the cytoplasm at 10 ng per oocyte and then after 4 h, the antisense was injected. All antisense treatments were carried out for 16 to 18 h (for significant depletion) by injecting 37.5 to 18.3 ng of the antisense DNA oligo or of the LNA (to block the microRNA target site) or a control antisense sequence (Oligonucleotides, siRNAs, and DNA Antisense includes sequences) into the animal pole side of the oocyte followed by injection of the reporters into the GV. All antisense oligonucleotides used to deplete proteins were DNA, and have been demonstrated to be effective at the concentrations used, even though DNA is more unstable than modified antisense (2, 3). The antisense DNAs targeted the ATG region; therefore, the depletion could be rescued by expression of a construct altered in the ATG region (4) by the presence of the λN tag (5) described in Oligonucleotides, siRNAs, and DNA Antisense. In all cases, the luciferase reporters and microRNA were injected together and last because the microRNA half-life is short (MicroRNAs and Quantifications).
RNA. mRNAs were transcribed using the T7 mMESSAGE mMACHINE Ultra transcription system (Ambion/Applied Biosystems), subjected to a G-50 spin column and gel purified; they were quantitated on a NanoDrop spectrophotometer. All luciferase reporters were capped and unadenylated. We did not see any stimulation over the increased translation observed with polyadenylated reporters. XlFXR1 cDNA was amplified as described later in Oligonucleotides, siRNAs, and DNA Antisense, and, along with the XlAGO and FXR1 clones, was used for T7 mMESSAGE mMACHINE Ultra transcription in the presence of anti-reverse cap analogues (ARCA) to produce ARCA-capped mRNAs as described for the T7 mMESSAGE mMACHINE Ultra transcription system (Ambion/Applied Biosystems). The mRNAs expressing these proteins were injected at 10 ng per oocyte 4 h before injection of the reporters and microRNA.
Reporters. Reporter mRNAs were transcribed using the T7 mMESSAGE mMACHINE Ultra transcription system (Ambion/ Applied Biosystems) in the presence of ARCA to produce ARCA-capped unadenylated mRNAs, then column-and gelpurified before quantification on a NanoDrop spectrophotometer. A total of 0.1 fmol (also 0.01 fmol) of each luciferase RNA per oocyte in 5 nL or 18 nL was injected into the GV.
miR16 Depletion. We find that siRNAs against pre-miR16 can act as antisense and lead to reduced mature miR16 after 6 h; the mechanism of depletion is unclear and may be a result of interference with processing or stability instead of cleavage activity, indirectly leading to decreased mature miR16. We depleted pre-miR16 overnight with 2.5 pmol of siRNA injected into the animal pole side of the oocyte for 12 to 16 h (300 fmol; 1 pmol could also be used) and then injected reporters 4-6 h before the assay. XlmiR16 levels were significantly depleted after 6 to 8 h of treatment with si-pre-miR16, whereas another microRNA, xlmiR148a, was unaffected (Fig.  S4B ). Let-7a was used as an siRNA control in parallel experiments. Half-life measurements of exogenous xlmiR16 yielded a short halflife of approximately 45 m (Fig. S4C ). The steady-state level of xlmiR16 was approximately 1 fmol/oocyte (Fig. S4D) , whereby the miR16 signal from RNA extracted from 10 oocytes was similar in intensity by PhosphorImager quantification to 10 fmol of synthetic xlmiR16 run alongside on the same Northern-blotted gel. It is unclear whether 300-to 2,500-fold excess siRNA over the mature microRNA (1 fmol/oocyte; Fig. S4D ) and potentially over the premicroRNA is required for depletion or whether the exogenous siRNA with a half-life under 1 h is required in these amounts to reach a 47-to 23-fold excess over the mature microRNA (1 fmol/ oocyte; Fig. S4D ) and potentially over the pre-microRNA at 6 to 7 h, after which the mature microRNA is depleted (Fig. S4B) . Expression of exogenous AGO2 enhances the efficiency of depletion, similar to previous reports in trypanosomes (6) and in mammalian cells (7) , suggesting that free (unbound to small RNA) AGO is limiting in the cell, perhaps accounting for the short halflives observed for exogenously added siRNAs/microRNAs.
MicroRNAs and Quantifications. To achieve up-regulated expression, from 20 fmol (harvested at 2-3 h) to 375 fmol (harvested between 4 and 6 h; Fig. 1B ) microRNA per oocyte were required with 0.1 fmol reporter (0.01 fmol of the reporters also showed activation). The microRNA levels rapidly decrease to the amounts seen in the blots during the incubation period, with a half-life of approximately 30 m for miRcxcr4 (Fig. S1A, i) . In contrast, the reporters are stable over 6 h (Fig. S1C, Upper) and show no significant change in half-life over the time frame used for our experiments or with the addition of the microRNA. This difference in stability (which may account for the short half-lives observed for exogenously added siRNAs/microRNAs) (7) might be the reason why the microRNA has to be introduced in excess. Not much is known about the synthesis and processing of microRNAs in oocytes. It takes 6 to 8 h to see depletion of the endogenous mature microRNA in oocytes when using an siRNA against the precursor. The half-life of exogenously added microRNA is short, approximately 30 to 45 m by either body labeling or by time-course measurements of unlabeled microRNA or by 5′-end labeling half-life experiments (Fig. S4C) . MicroRNA levels are reduced upon AGO depletion as previously reported in mammalian cells (7, 8) , suggesting that as in mammalian cells, free (unbound to small RNA) AGO is limiting in the oocyte and that microRNA levels are controlled in multiple ways, including processing and AGO levels.
A total of 0.20 fmol of 5′-
32
PγATP-labeled miRcxcr4 (5 pmol of miRcxcr4 was labeled in a 50-μL reaction with 30 U of T4 polynucleotide kinase and 300 μCi of 150 μCi/μL, 6,000 Ci/mmol 32 PγATP at 37°C for 1 h followed by gel purification on 16% urea PAGE) was injected into immature oocytes, five oocytes harvested at each time point, and the RNA was extracted, Northern blotted and analyzed on a PhosphorImager (Fig. S1A, i) , revealing a halflife of no more than 30 m. Thus, when 375 fmol of miRcxcr4 was injected, approximately 6 and 1.5 fmol/oocyte remained at 3 and 4 h after injection, when activation is observed (Fig. 1B) . This represents a 50-and 15-fold excess of microRNA over the mRNA, respectively, when injected along with 0.1 fmol reporter. RNase protection analysis (RPA) of miRcxcr4 at the times in Fig. 1B , using a miRcxcr4 probe, 5.8S rRNA as control, and a control synthetic microRNA sample of 1 fmol miRcxcr4, was performed (Fig. S1A , ii) to assess the cytoplasmic levels of miRcxcr4. We could detect the microRNA in the cytoplasm at 2 h and clearly see miRcxcr4 at 3 to 5 h, whereas at 6 h the microRNA was not observed by RPA (Fig. S1A, ii) and the up-regulation decreased (Fig.  1B) . Compared with the uninjected 1 fmol control, cytoplasmic microRNA levels at the 3 to 5 h time points were at least fivefold less by PhosphorImager quantification, which works out to be a maximum of 0.2 fmol. Given that half of 10 oocytes or five oocyte equivalents were loaded, this works out to be 0.04 fmol of microRNA in the cytoplasm per oocyte.
The amount of cytoplasmic luciferase mRNA produced from 0.0625 ng of DNA injected into the GV (isolated cytoplasm samples from Fig. 1B ) was quantified by RPA over time (Fig. S1C, Lower) . Quantification compared with 0.1 fmol in vitro-transcribed control luciferase mRNA demonstrates that at least 0.05 fmol luciferase mRNA appear in the cytoplasm and do not change with time or with miRcxcr4. Given that half of 10 oocytes or five oocyte equivalents were loaded per time point, this works out to be approximately 0.01 fmol per oocyte cytoplasm. As the microRNA (miRcxcr4) total level is approximately 1.5 fmol at 4 h (from the calculation earlier, total microRNA) and about 0.04 fmol in the cytoplasm/oocyte (from Fig. S1A , ii, calculated earlier), this works out to be approximately 30-fold excess total microRNA or fourfold excess cytoplasmic microRNA over the cytoplasmic mRNA (0.01 fmol/oocyte cytoplasm). Each target CX mRNA has four miRcxcr4 microRNA target base-pairing sites (9) .
A total of 0.50 fmol 5′- 32 PγATP-labeled xlmiR16 (labeled identically to miRcxcr4 except that 5 pmol B3/xlmiR16 were labeled) were injected into immature oocytes, five oocytes harvested at each time point, and the RNA extracted, Northern blotted and analyzed on a PhosphorImager with 5.8S rRNA as loading control. The half-life of exogenous xlmiR16 is approximately 45 m (Fig.  S4C) . The steady-state levels of endogenous xlmiR16 observed were approximately 1 fmol/oocyte, calculating from a titration whereby xlmiR16 from 10 oocytes was equivalent to 10 fmol synthetic microRNA run alongside on the same Northern gel (Fig.  S4D) . With a half-life of 45 min (Fig. S4C) , exogenous xlmiR16 introduced at 375 fmol/oocyte (3750 fmol/10 oocytes) should decrease to approximately 12-15 fmol/10 oocytes at 6 h when the oocytes are harvested. Therefore, the signal on the blots in Fig. 5C and Fig. S4A is approximately 12-15 fmol. Given that 10 oocytes per lane were loaded, there were approximately 1.2-1.5 fmol per oocyte, very similar to the result obtained from the titration of synthetic xlmiR16 alongside an endogenous sample of 10 oocytes (1 fmol/oocyte; Fig. S4D ). B1 is trimmed to B3 in oocytes and similar half-lives were observed by reprobing blots of injected unlabeled or body-labeled microRNAs. The amount of miRcxcr4 present at 4 h, which is approximately 1.5 fmol per oocyte (when activation is observed) as calculated from its half-life in the previous paragraph, is comparable to the level of the endogenous xlmiR16 at 1 to 1.5 fmol per oocyte.
cAMP Protocol. PKA acts as either PKAI or PKAII as a result of modulation of the catalytic subunit by alternative cofactors, repressor I (RI or RIα) or II (RII or RIIβ) subunits (10); both RI and RII respond to cAMP levels, with RII requiring increased cAMP (10) (11) (12) ). An increased RI/RII ratio is associated with proliferation and an increased RII/RI ratio with growth arrest (13, 14) . RI/ PKAI is aberrantly overexpressed in tumor cell lines commonly used in laboratories and leads to down-regulation of RII enabling uncontrolled proliferation (10) ; this may lead to difficulties in inducing G0 arrest in different tumor cell lines. PKAII signaling is induced by a relative increase in cAMP levels (15) , rather than by total levels of cAMP.
The cAMP-inducing drug (16, 17) , N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt (dibutyryl cAMP; Sigma, 100 mM in water) was injected into the animal pole side of the oocyte (2 fmol/oocyte), whereas other agents-papaverine [Sigma; 10 mg/mL stock solution in 50% ethanol; add 50 μL or 0.300 mM to 5 mL of OR2 oocyte buffer (1) containing the oocytes in Petri plates], forskolin (1 mg/mL in water; add approximately 20-40 μL or 5-10 μM; LC Laboratories) or the water/ethanol control-were simply added to the OR2 oocyte buffer on the plates and mixed by tilting. Dibutyryl cAMP injections were performed before defolliculation; after defolliculation and resting overnight, the oocytes were injected with the reporters and microRNAs and harvested after 4 h incubation. Papaverine was simply added to the media of oocytes that were simultaneously defolliculated, followed by resting overnight, and then injected with the reporters and microRNAs followed by a 4-h incubation before harvest. All drugs were made up fresh before addition. It is essential that the papaverine stock is completely dissolved.
A total of 0.0625-0.125 ng/oocyte of PKA regulatory subunit plasmids, RI, RII, C (10-12), as well as other signaling regulators (PAK and its mutants, MEKDD, RAF mutants, and all signaling regulators), were injected as plasmids into the nucleus 4 h before injection of the microRNA and reporters into the nucleus. The oocytes were harvested after a second subsequent 4-h incubation.
cAMP Quantification. cAMP screen system (Applied Biosystems) was used following the manufacturer's instructions. Two sets of 1 × 10 4 HeLa cells per plate were prepared. Three hours later, after washing the cells three times with PBS solution, for one set of cells, the medium was replaced with serum-minus medium and immediately transfected with 0.4 μg Hes1 to maintain quiescence (i.e., serum starvation). For the other set of cells, the media were replaced with serum-plus media and transfected with 0.4 μg GFP (i.e., serum-grown control). The cells were harvested after 36 h by trypsinization followed by three washes in PBS solution. Extracts were prepared as described for the cAMP screen system (Applied Biosystems) using 60 μL of the provided lysis buffer. Immature, defolliculated or matured oocytes (approximately five oocytes per sample) were lysed using 60 μL of the provided lysis buffer, clarified by centrifuging at 2,000 × g for 5 m, and 25 μL of the extract was used following the cAMP screen system instructions. Luminescence was measured on a plate luminometer.
cAMP Calculations. PKAII signaling required for arrest is induced by a relative increase in cAMP levels (15) , rather than the total cAMP level. Xenopus oocytes in the immature state have approximately 6 pmol of cAMP per oocyte that varies between frogs (Fig. S2A, i) , which are reduced by 25% upon defolliculation (4.5 pmol/oocyte) and by half upon maturation (3 pmol/ oocyte; Fig. S2A, i) , and has been shown to correlate with physiologically significant changes (18) (19) (20) .
Mammalian quiescent cells have approximately 86 × 10 −6 pmol/ cell cAMP, whereas proliferating cells were at background levels with 0.36 × 10 −6 pmol/cell (Fig. S2A, ii) , similar to earlier studies (21) (Fig. S2A, ii) . The oocyte has 6 pmol/0.9 μL = 6.7 pmol/μL cAMP (Fig. S2A, ii) .
Protein Analyses. Protein analyses were as previously described (22) .
Antibodies and Oocyte Extract Analyses. Anti-AGO or pan-AGO, also called 2A8 (23), was used primarily for immunoprecipitations, as this antibody has been reported to be best for immunoprecipitating AGO2-associated mRNAs (24) . It was used for only one Western in Fig. S3C (anti-AGO/2A8) to compare with the specific AGO2 antibody (anti-AGO2 panel; Millipore). Anti-AGO2 (Millipore/Upstate) (22, 25) was used for all Western blots, and also immunoprecipitated AGO. Anti-Myt1 and anti-phospho-CDC2 was from Cell Signaling. Anti-FXR1 was obtained from G. Dreyfuss, and anti-FXR1 (Y19) was from Santa Cruz. Anti-actin and FLAG were from Sigma (polyclonal and monoclonal antibodies). Anti-tubulin was from Upstate (for mammalian extracts) and anti-β-tubulin was from Santa Cruz (for Xenopus extracts). Anti-Firefly was from Millipore. Anti-Renilla was from MBL.
Xenopus AGO-Like Protein. The AGO-like protein cloned from Xenopus is identical in sequence to an eIF2C2 clone present in the database (NM_001093519) and is similar to a second related clone in the database (EU338243). Although the mammalian AGO2-specific and pan-AGO (2A8) antibodies detect the expressed cDNA ( Fig. 3A and Fig. S3 A and C) , it remains unclear whether the Xenopus AGO is an AGO2 orthologue in the absence of characterization of known human AGO2 functions such as slicer activity; therefore, we refer to the cDNA identified as xlAGO on the basis of its sequence identity to the Argonaute family. The existence of other AGO forms in Xenopus cannot be ruled out. Xenopus clones for AGO1 and AGO3 are unavailable. We could not detect expression from a putative Xenopus AGO4 clone by any antibody.
The antibody used for Westerns (anti-AGO2; Millipore) was verified by its detection of Flag-tagged human AGO2 and Flagtagged Xenopus AGO expressed in AGO antisense-treated oocytes, which provided a clean background (Fig. 3A and Fig. S3 A and C, anti-AGO2). No other band is detected by the anti-AGO2 antibody, which recognizes expression from the hAGO2 and xlAGO clones only and not from hAGO1, hAGO3, and hAGO4 clones (Fig. 3A and Fig. S3 A and C, anti-AGO2 ). The endogenous band (Fig. S3A, lane 1) detected by anti-AGO2 is depleted upon AGO antisense treatment of the oocytes (Fig. S3A, lane 2, and Fig. S3C, lane 1) and then restored by expression of cloned xlAGO (Fig. S3A, lane 3, and Fig. S3C, lane 6) , confirming that the endogenous band is xlAGO. The pan-AGO/2A8 and Flag antibodies detect all cloned hAGO and the cloned xlAGO expressed in the xlAGO antisense-treated oocytes (Fig. S3C , anti-AGO/2A8 and anti-Flag). Significant depletion of AGO takes at least 16 h (and 4 h for xlFXR1), as shown in Fig. 3 A and B and Fig. S3 A, C, D , and E. The DNA antisense targets the ATG region and can be rescued by expression of the λN tagged construct, altered at the ATG region by the tag (8) . The λN-tagged versions of human AGO2 and Xenopus AGO expressed as mRNAs were the only proteins that rescued translation (Fig.   S3B ). Human AGO1, AGO3, and AGO4 have less significant effects on activation (Fig. S3B) . XlAGO rescued translation as significantly as hAGO2 (Fig. S3B ) but was less well expressed (Fig. S3C , anti-AGO/2A8 and anti-Flag); this suggests that activation is dependent on the specific AGO expressed rather than on the level of expression.
Xenopus AGO protein is not easily detectable in soluble extracts with a 10,000 × g centrifugation for clarifying the extract. Most of the AGO precipitates in such a protocol, suggesting lack of disruption of aggregation or AGO association with a high molecular weight complex in these extracts. However, soluble lysates produced by clarification at low centrifugation speeds (as detailed later) and sonicated SDS lysis extracts (sonicated and SDS lysed before low-speed clarification) of oocytes (with previous defolliculation to remove follicle contamination) contain AGO. Loss of the band detected by anti-AGO2 antibody upon antisense treatment followed by rescue of the band with expression of cloned AGO (human AGO2 and Xenopus xlAGO; Fig. S3 A and C) confirms AGO presence. The detected AGO protein is replaced by a slightly faster migrating and more abundant band upon maturation, suggesting that alternate AGO forms may take over those studied in immature oocytes.
Oocyte Extract Preparation and Immunoprecipitations. Oocyte samples marked defolliculated were given an overnight rest after defolliculation before harvest/further analyses. Apart from this, all of the extracts (for RNA and protein analyses) were prepared only after collagenase treatment followed by manual defolliculation and examination to ensure complete defolliculation (1) . We see no significant difference as a result of the presence of follicles by Western analyses and detected no signal upon analysis of the separated follicle layers. Soluble extracts for immunoprecipitations were prepared by manually crushing oocytes (20 oocytes per sample) in 75 μL of lysis buffer X (150 mM NaCl, 40 mM Hepes 7.8, 6 mM MgCl 2 , 0.05% Nonidet P-40, 10% glycerol) and adding DTT and PMSF to 1 mM each. The extract was incubated on ice for 20 m. Low amounts of AGO are present in extracts if the extracts are clarified at 10,000 × g. Therefore, a low-speed centrifugation (2000 × g) was used to clarify the extracts for immunoprecipitations. A pipette tip was used to clear the lipid layer and the clarified extract removed to a new tube. The immunoprecipitations were carried out with these soluble lysates of the oocytes (Fig. 3E ) by using anti-pan-AGO/2A8 antibody.
One half of the extract was diluted twofold with lysis buffer X and incubated with 6 μL anti-AGO antibody (the pan-AGO/2A8 antibody was used for immunoprecipitations and for one Western blot, Fig. S3C , anti-AGO/2A8; while the AGO2-specific antibody was used for all Western blots) or anti-FLAG (Fig. 3E) as control antibody overnight with nutation at 4°C. The samples were then transferred to new tubes, 50 μL of protein G agarose added, followed by incubation with nutation at 4°C for 1 h after which the beads were concentrated by centrifugation at 6,000 × g for 10 m. The agarose beads were washed with lysis buffer X without DTT and glycerol thrice and then transferred to a new tube for acetone precipitation followed by or directly resuspended in 6× loading buffer with 0.4 M DTT. For immunoprecipitations for RT-PCR assays (Fig. 3E) , 0.5 μL of RNasin was added to the extract before incubation with the antibody and the immunoprecipitates were used for RNA extraction/analyses. Twenty oocytes were used for each sample.
For all gels, equal numbers of oocytes (20 defolliculated oocytes upon harvest, isolated as described in ref. 1) were run in each lane. To analyze AGO levels by Western blotting, total oocytes (defolliculated upon harvest) were prepared as sonicated lysates (Fig. 3A and Fig. S3 A and C) . Total defolliculated oocytes were lysed and extracted on ice for 20 m in lysis buffer X, followed by clarifying the sample at 2,000 × g for 5 m to separate out and remove the lipid/polysaccharide layer. The rest (lysate and resuspended pellet) was made up to 0.3% SDS, extracted on ice, and sonicated for 10 s with 30 s cooling three times, and the subsequent sonicated lysate clarified by centrifugation at 2,000 × g for 5 m to remove debris, followed by acetone precipitation of the sonicated samples. The precipitates in SDS loading buffer were fractionated by 4% to 20% gradient SDS/PAGE followed by Western blotting and further analyses; the anti-AGO2 antibody was used for hAGO2 and xlAGO detection, whereas antiFlag antibody or pan-AGO/2A8 antibodies were used for all cloned human and Xenopus Argonautes (Fig. S3C) .
Protein Half-Life Analyses.
35
S pulse labeling of oocytes was performed by adding 1 mCi of EasyTag Express 35 S protein labeling mix (consisting of a mix containing 35 S-methionine; PerkinElmer) to 2 mL OR2 buffer (1), in which oocytes that had been injected 2 h earlier with 0.0625 ng of DNA expressing Firefly and Renilla luciferase, were incubated for 20 m. For xlAGO and xlFXR1 halflives, the oocytes were not injected with reporters and were incubated for 2 h with 35 S protein labeling mix. Then, the OR2 buffer containing the oocytes was replaced three times to clear the oocytes of the [ Fig. S1B and Fig. S3E ). Twenty oocytes were harvested at each time point. The oocytes were then subjected to extract preparation and immunoprecipitation as described earlier by using antiFirefly, anti-Renilla, anti-AGO, and anti-FXR1 antibodies, washed with RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.05% SDS, 150 mM NaCl, and 50 mM Tris 7.0) and twice with lysis buffer. The immunoprecipitates were run on 4% to 20% SDS/PAGE, the gels transferred onto nitrocellulose and analyzed on the PhosphorImager.
RNA Analysis. Total RNA was prepared from mammalian cells as described previously (22, 25) . Ten oocytes were used for each RNA sample except in Fig. S1A , i, and Fig. S4C (five oocytes) and in Fig. S1A , ii, and Fig. S1C , Lower, in which five oocyte equivalents of cytoplasm were used in each lane. Oocytes were first treated to remove the follicle layers, digested with proteinase K, and total RNA extracted by phenol:chloroform and ethanol precipitation (1, 27) . The RNA was then subjected to DNase I treatment and reextracted by phenol:chloroform and ethanol precipitation. RNA was fractionated by 15% PAGE with 8 M urea, Northern blotted, and probed with T7 runoff antisense RNA probes to detect microRNAs. The probes for all microRNA blots and for all RPAs were transcribed from T7 templates, which were created by annealing two oligonucleotides: oligo 1 bears the T7 promoter sequence (TAATACGACTCACTATAGGG), followed by a CATGC spacer sequence, followed by the antisense of the microRNA or test sequence; oligo 2 was the reverse complement to oligo 1. U6 RNA and 5.8S rRNA were probed as loading controls using RPAs. RPAs were performed as described previously (22, 25) . RPA was performed by using the probes described earlier (5 × 10 4 cpm of each probe), denatured at 95°C for 4 m with the sample in a 100-μL reaction (hybridization buffer, 40 mM Pipes, pH 6.4, 1 mM EDTA, 0.4 M NaCl, 80% formamide), hybridized at 45°C for 6 h and digested with 2 μg of RNase A and 0.6 U of RNase T1 at 30°C for 30 m with 300 mM NaCl, 10 mM Tris, pH 7.5, and 5 mM EDTA. The protected RNA was digested with proteinase K, phenol:chloroform extracted and subjected to 6% PAGE, dried, and quantified by a PhosphorImager (Molecular Dynamics). T7 runoff antisense probes against the microRNAs were used for RPA according to the MirVANA miRNA detection system instructions (Applied Biosystems). All RNA analyses were performed in triplicate.
Splint Ligations. Bridge oligonucleotides were designed to be complementary to the various 5′ ends (B1-4) of xlmiR16 and to the 14-nt acceptor such that ligation would occur only if the 5′ end of xlmiR16 were correct; this takes advantage of the 5′-monophosphate that distinguishes the microRNA from degradation products. Splint ligation of 5′ 32 P-labeled acceptor was performed as described (28, 29) without the phosphatase step, using 0.01 pmol of the splint oligos and total stage IV-VI oocyte RNA or anti-AGO2 or antiFlag immunoprecipitated oocyte RNA. Control synthetic microRNAs designed to mimic the respective 5′ ends of xlmiR16 were used as controls and size markers, whereas tRNA or RNA from anti-Flag immunoprecipitates provided a negative control. Reactions were digested with proteinase K, phenol:chloroform extracted, ethanol precipitated, fractionated by 15% PAGE, dried, and exposed to the PhosphorImager.
RT-PCR Analyses. cDNA synthesis was performed using FF3END3 (caatttggactttccgcccttcttggc) and the cDNA was subjected to touchdown PCR (95°C denaturation for 45 s, 20 cycles touchdown from 68°C to 48°C annealing for 30 s, 72°C extension for 30 s, 18 cycles of amplification at 48°C with 95°C denaturation for 45 s, 48°C annealing for 30 s and 72°C extension for 30 s). Primers FF3END3 (caatttggactttccgcccttcttggc) and FF10-5 (ggattacgtggccagtcaagtaacaaccg) were used to amplify CX Firefly internally at the 3′ end upstream of the stop codon (Fig. 3E ) and analyzed by ethidium bromide staining of agarose gels.
Plasmids. The 3′-UTR of Myt1 mRNA was amplified by RT-PCR and cloned into the Not I site of the CTRL plasmid (22, 25, 30) . A 528-nt region encompassing the seven putative xlmiR16 sites from Myt1 was also cloned as a Not I insert into the CTRL reporter as described later. The sites were mutated as indicated by QuikChange as described by Stratagene. XlAGO was amplified and cloned as an XhoI-EcoRI fragment bearing a 5′-Flag tag into the λN vector (5). XlFXR1 cDNA was amplified as described later, and, along with the XlAGO clone, was used for T7 transcription in the presence of ARCA to produce ARCA-capped mRNAs as described for the T7 Ultra mMESSAGE mMA-CHINE transcription system (Ambion/Applied Biosystems). Plasmids for expressing RI, C, and RII were obtained from Open Biosystems, for Flag-tagged hAGO1-hAGO4 (31, 32) , PAK mutants (33, 34) , RAFv600E, and MEKDD (35) from Addgene, and the λN-tagged Argonautes from W. Filipowicz (36) .
Oligonucleotides, siRNAs, and DNA Antisense. All siRNAs and miRNAs listed in this section had a 5′-monophosphate on the guide siRNA or miRNA strand, were designed, annealed, and introduced as double-stranded siRNAs (9, 37) , synthesized by Integrated DNA Technologies. MicroRNAs let-7a, miR369-3p, and miRcxcr4 were described earlier (9, 25, 30, 37) . The si-prexlmiR16 used throughout, except where stated otherwise, included both silp16a and silp16c. silp16a: AAUAUUGGGACCAUUUUAATT; UUAAAAU-GGUCCCAAUAUUUA silp16c: UUAAAAUGGUCCCAAUAUUTT; AAUAUUG-GGACCAUUUUAATT xlmiR16: UAGCAGCACGUAAAUACUGGAG; CCAGU-AUUUACGUGUUGUUAUU Let-7a was used as a parallel control: UGAGGUAGUAGG-UUGUAUAGU; UAUACAACCUACUACCUCAUU.
xlmiR16B1-B4 (Fig. 4C ) were as follows: B1, UAGCAG-CACGUAAAUACUGGAG and CCAGUAUUUACGUGUU-GUUAUU; B2, AGCAGCACGUAAAUACUGGAG and CC-AGUAUUUACGUGUUGUUUU; B3, GCAGCACGUAAA-UACUGGAG and CCAGUAUUUACGUGUUGUUU; B4, CAGCACGUAAAUACUGGAG and CCAGUAUUUACGU-GUUGUU LNAmyt: CUUUA+ACG+TCA+CCA+ACA+CGU+AAG+ AUUC (+depicts LNA, all others are 2′-O-methylated). XlmtmiR16: UAGuAcgACGUAAAUACUGGAG; CCAGUAUUUACGUcgUaUUAUU Xlmt3miR16: UguuAGCACGUAAAUACUGGAG; CCAGUAUUUACGUGUUaauAUU For splint oligonucleotides B1 to B4: All splint oligos were blocked at both ends by a 5′ C3 spacer and a 3′ C3 spacer (C3 = 3 carbons). The uppercase nucleotides correspond to the first 16 nt of the various xlmiR16 forms. The lowercase nucleotides will base pair with the acceptor oligonucleotide. B1, TATTTACGTGCTGCTAcgtagtcgatcagc; B2, TATTTACGTGCTGCTcgtagtcgatcagc; B3, TATTTACGTGCTGCcgtagtcgatcagc; B4, TATTTACGTGCTGcgtagtcgatcagc. Acceptor oligonucleotide: gctgatcgactacg.
All antisense oligonucleotides were DNA, which at the concentrations used (DNA Plasmids and Antisense) have been demonstrated to be effective even though DNA is more unstable compared with modified antisense (2, 3) . The antisense targets the ATG region; therefore, the depletion can be rescued by expression of a tagged construct, altered at the ATG region by the presence of the λN tag (4), specifically the (ATGAACGCA-CGAACACGACGACGTGAGCGTCGCGCTGAGAAACAA-GCTCAATGGAAAGCTGCAAAC) λN tag (5).
Antisense AGO: CAAGCACCGGCCCGGCCCCGGAGTA-CAT and CAAGCACCGGCCCGGCCCCGGAGGACAT Antisense FXR1: GCACTTCCACCGTCATGTCCTCCAT Control antisense (Fig. 3 A and B and Fig. S3 B and C) : CAAGTAGTGATTCACCGTAGCTGCTGTGG All mutations were derived by QuikChange (Stratagene). Primers used for cloning were as follows.
Myt1 3′-UTR: AAG GAA AAAA GCGGCCGC TAG CAG TGC AGA GTA CCA CAC AGC and AAG GAA AAAA GC-GGCCGC TCTC TTT TTT CT CCC AATT CAG CTTT GTTG amplified the full-length (+63nts more) Myt1 3′-UTR, which was cloned into the Not I site of CTRL as described earlier (22) . The xlmiR16 site is at 1,284 nt downstream of the stop codon, where base pairing with the microRNA begins.
A total of 528 nt of the Myt1 3′-UTR containing the xlmiR16 candidate sites AAG GAA AAAA GCGGCCGC GTC TTC CGG TTC GTG ACA ACT GTG and AAG GAA AAAA GCGGCC-GC GA TTT CTT CTT AGT ACT GTC TGC GTG amplified the 528-nt region of the Myt1 3′-UTR containing the putative xlmiR16 sites (802-1330 nt from the stop codon), which was cloned into the Not I site of CTRL as described earlier (22) .
FXR1: CCG CTC GAG GAGGACA TGACGGTGGA AGTGCGCGG and CCG GAATTC TTA CTT GTC ATC GTC GTC CTT GTA GTC AGA CAC CCC ATT CAT TAT GGC TTC TTG amplified the FXR1 ORF as a XhoI fragment from FXR1 cDNA (derived from total RNA using identical primers without the XhoI restriction sites and cloned). A T7-λN tagged 5′ primer (5, 22) with the C-terminal FLAG tag added by the 3′ primer was used for the production of a PCR fragment that served as template for in vitro transcription of the λN FXR1-Flag transcript, which was capped and used for injections.
AGO: CCG CTCGAG GAC TAC AAG GAC GAC GAT GAC AAG TACTC CGGGGCCGGG CCGGTGCTTG TTC and CCG GAATTC TTA TGC AAA GTA CAT TGT ACG CAG TGTGTC amplified the AGO ORF as a XhoI-EcoRI fragment bearing an N-terminal Flag tag, amplified from AGO cDNA (amplified from total RNA using identical primers without the XhoI 5′ and EcoRI 3′ restriction sites or the FLAG tag sequence in the 5′ primer). The fragment was further cloned as an XhoI-EcoRI fragment into the λN vector (5) with the FLAG tag added by the 5′ primer. A T7-tagged primer was used for the production of a PCR fragment that served as template for in vitro transcription of the AGO transcript, which is capped and used for injections. 32 PγATP-labeled miRcxcr4 were injected into immature oocytes; five oocytes were harvested at each time point and the RNA extracted, Northern-blotted, and analyzed on a PhosphorImager. (ii) RPA of miRcxcr4 present in the cytoplasm at the times analyzed in Fig. 1B , with 5.8S rRNA as a control; 1 fmol of miRcxcr4 synthetic microRNA was loaded on the left. The injected miRcxcr4 that appears in the cytoplasm at 3-5 h (when activation is observed in Fig. 1B) is at least fivefold less than the uninjected 1 fmol control (0.2 fmol, by PhosphorImager quantification). Given that the cytoplasm from an equivalent of five oocytes was analyzed on the gel, this equates to approximately 0.04 fmol miRcxcr4 per oocyte cytoplasm. At 6 h, the microRNA is no longer detected, likely in part as a result of its short half-life. Given the amount injected (375 fmol as for activation assays), the short half-life, and the detection limit of RPA, the microRNA appearing in the cytoplasm does not depict mature microRNA export rates but simply shows that it is exported and present in the cytoplasm during the time that activation is observed. (B) Firefly and Renilla luciferase proteins have half-lives of 45 m and 1.5 h, respectively. DNA constructs encoding Firefly or Renilla luciferase were injected into oocytes. Two hours later, the oocytes were pulse-labeled with [ (19, 20) . Defolliculated and matured oocytes show profound differences in signaling effects compared with the immature folliculated oocytes even though the differences in cAMP levels, as observed earlier (19, 20) , is no greater than twofold.
(ii) To compare the cAMP levels between frogs and human cells (immature oocytes vs. serum-grown and serum-starved HeLa cells), the cAMP/μL was calculated (SI Methods, cAMP Quantification), as each oocyte is very large in volume (1.2 mm, 0.9 μL) compared with a HeLa cell (1.8 × 10 Anti-ePAB Fig. S3 . AGO or the Xenopus AGO-like orthologue, xlAGO, can rescue microRNA-mediated up-regulated expression after antisense depletion of the endogenous AGO-like orthologue, xlAGO. Oocytes were injected cytoplasmically with in vitro-transcribed mRNAs encoding GFP, hAGO1-hAGO4 ( Fig. S3 B and C) , or xlAGO (the Argonaute clones are all Flag-tagged) and 4 h later with 37.5 ng of DNA oligonucleotide antisense to xlAGO or a control scrambled antisense (Oligonucleotides) into the animal pole side. After incubation for at least 16 h, the GVs were injected with the reporters and microRNAs, and 3 to 4 h later, the oocytes were defolliculated and harvested for luciferase assays (B) or for Western blotting shown in A and C as described in SI Methods. (A) Western blot using a specific AGO2 antibody (anti-AGO2; Millipore) reveals that oocyte AGO levels (lane 1) are significantly depleted 16 h after injection of a 28-nt-long oligonucleotide antisense to the xlAGO coding sequence as described in SI Methods (lane 2). The band is restored by expression of the xlAGO clone, which is resistant to the antisense as a result of its λN tag (lane 3). Actin (the polyclonal antibody used here detects several forms; Sigma) is the loading control. (B) Luciferase assays of oocytes treated as described earlier. λN-tagged hAGO2 and λN-tagged xlAGO significantly rescued the microRNA-mediated up-regulation (control antisense-treated) that was abrogated by the antisense to xlAGO (xlAGO antisense with GFP expression as a control). hAGO1, hAGO3, and hAGO4 had less significant effects on activation compared with hAGO2 and xlAGO. (C) Western blotting of the samples in B revealed that the anti-AGO2 antibody (Millipore) detects a band only in the oocytes expressing hAGO2 and xlAGO (anti-AGO2, lanes 3 and 6). When the pan-AGO/2A8 antibody (23) was used to reprobe the same blot, the expression of hAGO2-4 clones (lanes 3-5) and the xlAGO clone (anti-AGO/2A8, lane 6) was verified, with faint detection of hAGO1 (lane 2). Lower: Second gel with the same samples Western blotted with anti-Flag, which validated the expression of all four hAGOs (lanes 2-5) and xlAGO (lane 6), with hAGO2 (lane 3) expressed the best and hAGO4 (lane 5) and xlAGO (lane 6) expressed least. Tubulin was the loading control. The faint signal detected in the lane for hAGO4 could be faint cross-reactivity with the remaining endogenous xlAGO after depletion. XlAGO is similar overall but not identical to hAGO2 and is not expected to migrate identically. (D) Time course after injection of 37.5 ng of DNA oligonucleotide antisense to xlAGO (Upper) or xlFXR1 (Lower) mRNA (SI Methods, Oligonucleotides, siRNAs, and DNA Antisense) into the animal pole side. ePAB was detected as loading control. (E) Half-lives of xlAGO and xlFXR1 proteins, respectively. The oocytes were pulse-labeled with [ 35 S]methionine/protein labeling mix (PerkinElmer) for 2 h, followed by 1 mM nonradioactive methionine chase. A total of 20 oocytes were harvested at each time point and the resulting extracts were subjected to immunoprecipitation with anti-AGO and anti-FXR1 antibodies (SI Methods); the immunoprecipitates (Ip) were run on SDS/PAGE, Western-blotted, and then visualized by PhosphorImager. The lower band in the FXR1 immunoprecipitate is a degradation product. Endogenous xlmiR16 levels decrease after at least 6 to 8 h of treatment of oocytes with siRNAs antisense to pre-xlmiR16 (a, siRNA against pre-miR16a; all, siRNAs against pre-miR16a and pre-miR16c), but not with control siRNA (let-7a) and are restored by the addition of synthetic mature B3/xlmiR16, as shown by Northern blotting for xlmiR16; U6 is loading control. (B) Endogenous xlmiR16 levels decrease after 6 h of treatment with si-pre-miR16 antisense; the mechanism of depletion is unclear and may be a result of interference with processing or stability instead of cleavage activity. In contrast, another microRNA, xlmiR148a, is unaffected as shown by Northern blotting of RNA samples of oocytes defolliculated and harvested at the time points shown after injecting si-pre-miR16 (SI Methods). (C) Half-life measurements of exogenous B3/xlmiR16 indicate a half-life of approximately 45 m. A total of 0.50 fmol 32 PγATP-labeled xlmiR16 was injected into immature oocytes, five oocytes harvested at each time point, and the RNA extracted, Northern blotted, and analyzed on a PhosphorImager with 5.8S rRNA as loading control. B1 is trimmed to B3 in oocytes and similar half-lives were observed by reprobing blots of injected unlabeled or body labeled microRNAs. (D) Titrations (100 fmol and 10 fmol) of uninjected xlmiR16 (B3/xlmiR16) were compared by Northern blotting to endogenous xlmiR16 present in RNA extracted from 10 untreated oocytes or 10 oocytes pretreated with si-pre-miR16, as described in SI Methods; 5.8S rRNA served as a loading control. , si-pre-miR16-depleted oocytes (si-pre-miR16+GFP), rescue with B3/xlmiR16 (si-pre-miR16+ xlmiR16/B3), and rescue with Myt1 expression (si-pre-miR16+Mytctrlutr). The oocytes lacking Myt1 expression and thereby lacking CDC2 phosphorylation (LNAmyt+GFP and si-pre-miR16+GFP) have aberrant white spots as a result of anomalous loss of immaturity (26) .
